Stockholm, 15th of May, 2025 – Alder Therapeutics a pioneering replacement cell therapy company developing treatment for degenerative eye diseases and cardiac diseases, today announced that it has been granted patents for its lead program targeting retinitis pigmentosa (RP) in both the United States and Singapore. These patents cover the company’s novel therapeutic approach and are a significant step in securing global protection for its core technology.
Retinitis pigmentosa is a group of inherited retinal diseases that lead to progressive vision loss and currently lacks effective treatments. Alder Therapeutics’s innovative therapy aims to preserve and restore visual function by replacing lost or damaged retinal cells.
“We are proud to have secured these important patents in two key jurisdictions,”
said Kristian Tryggvason, CEO of Alder Therapeutics
“This is a major milestone that strengthens our intellectual property position and supports our mission to bring transformative treatments to patients suffering from retinal degenerative diseases. It also reflects the strength and uniqueness of our science as we move towards clinical development.”
Alder Therapeutics is a virtual pre-clinical replacement cell therapy development company that is shaping the future of regenerative medicine. Founded in 2022 by seasoned cell therapy and industry experts, the company has two promising allogeneic stem cell therapy programs in the pipeline: one for degenerative eye diseases, and one for chronic heart disease. At the core of the company’s success is the AlderEdge™ platform — a novel approach to cell therapy development that keeps the commercial product in mind from the start for a de-risked route to success.
Kristian Tryggvason
CEO
Alder Therapeutics
kristian@aldertx.com
Want to support us on our journey to shape the future of regenerative medicine?
